<p>|Recommendation|Level of evidenceâ€ |
|---|---|
|In adult patients with active PsA despite treatment with an IL-17i biologic monotherapy,| |
|1. Switch to a TNFi biologic over switching to an IL-12/23i biologic (PICO 39)|Very low|